File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effect of interferon alpha and cyclosporine treatment separately and in combination on Middle East Respiratory Syndrome Coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo culture model

TitleEffect of interferon alpha and cyclosporine treatment separately and in combination on Middle East Respiratory Syndrome Coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo culture model
Authors
KeywordsCyclosporine
Ex vivo explants
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Type I interferon
Issue Date2018
Citation
Antiviral Research, 2018, v. 155, p. 89-96 How to Cite?
AbstractMiddle East Respiratory Syndrome Coronavirus (MERS-CoV) has emerged as a coronavirus infection of humans in the past 5 years. Though confined to certain geographical regions of the world, infection has been associated with a case fatality rate of 35%, and this mortality may be higher in ventilated patients. As there are few readily available animal models that accurately mimic human disease, it has been a challenge to ethically determine what optimum treatment strategies can be used for this disease. We used in-vitro and human ex-vivo explant cultures to investigate the effect of two immunomodulatory agents, interferon alpha and cyclosporine, singly and in combination, on MERS-CoV replication. In both culture systems the combined treatment was more effective than either agent used alone in reducing MERS-CoV replication. PCR SuperArray analysis showed that the reduction of virus replication was associated with a greater induction of interferon stimulated genes. As these therapeutic agents are already licensed for clinical use, it may be relevant to investigate their use for therapy of human MERS-CoV infection.
Persistent Identifierhttp://hdl.handle.net/10722/258395
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLI, HS-
dc.contributor.authorKuok, IT-
dc.contributor.authorCheung, MC-
dc.contributor.authorNG, MT-
dc.contributor.authorNg, KC-
dc.contributor.authorHui, PY-
dc.contributor.authorPeiris, JSM-
dc.contributor.authorChan, MCW-
dc.contributor.authorNicholls, JM-
dc.date.accessioned2018-08-22T01:37:47Z-
dc.date.available2018-08-22T01:37:47Z-
dc.date.issued2018-
dc.identifier.citationAntiviral Research, 2018, v. 155, p. 89-96-
dc.identifier.urihttp://hdl.handle.net/10722/258395-
dc.description.abstractMiddle East Respiratory Syndrome Coronavirus (MERS-CoV) has emerged as a coronavirus infection of humans in the past 5 years. Though confined to certain geographical regions of the world, infection has been associated with a case fatality rate of 35%, and this mortality may be higher in ventilated patients. As there are few readily available animal models that accurately mimic human disease, it has been a challenge to ethically determine what optimum treatment strategies can be used for this disease. We used in-vitro and human ex-vivo explant cultures to investigate the effect of two immunomodulatory agents, interferon alpha and cyclosporine, singly and in combination, on MERS-CoV replication. In both culture systems the combined treatment was more effective than either agent used alone in reducing MERS-CoV replication. PCR SuperArray analysis showed that the reduction of virus replication was associated with a greater induction of interferon stimulated genes. As these therapeutic agents are already licensed for clinical use, it may be relevant to investigate their use for therapy of human MERS-CoV infection.-
dc.languageeng-
dc.relation.ispartofAntiviral Research-
dc.subjectCyclosporine-
dc.subjectEx vivo explants-
dc.subjectMiddle East Respiratory Syndrome Coronavirus (MERS-CoV)-
dc.subjectType I interferon-
dc.titleEffect of interferon alpha and cyclosporine treatment separately and in combination on Middle East Respiratory Syndrome Coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo culture model-
dc.typeArticle-
dc.identifier.emailCheung, MC: bccmc@hku.hk-
dc.identifier.emailNg, KC: kckachun@hku.hk-
dc.identifier.emailHui, PY: kenrie@hku.hk-
dc.identifier.emailPeiris, JSM: malik@hkucc.hku.hk-
dc.identifier.emailChan, MCW: mchan@hku.hk-
dc.identifier.emailNicholls, JM: jmnichol@hkucc.hku.hk-
dc.identifier.authorityHui, PY=rp02149-
dc.identifier.authorityPeiris, JSM=rp00410-
dc.identifier.authorityChan, MCW=rp00420-
dc.identifier.authorityNicholls, JM=rp00364-
dc.identifier.doi10.1016/j.antiviral.2018.05.007-
dc.identifier.scopuseid_2-s2.0-85047058929-
dc.identifier.hkuros286583-
dc.identifier.volume155-
dc.identifier.spage89-
dc.identifier.epage96-
dc.identifier.isiWOS:000437046700010-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats